Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 6 of 27
A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
NCT06049108
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
NCT06039826
A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants
NCT06028425
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
NCT06003465
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT06007651
A Study of LY3871801 in Healthy Asian and Non-Asian Participants
NCT05960851
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
NCT05971940
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
NCT05978713
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
NCT05906836
A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants
NCT05959109
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
NCT05959096
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
NCT05916560
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
NCT05936138
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT05911841
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
NCT05882032
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
NCT05887999
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
NCT05894928
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620
A Study of [14C]-LY3537982 in Healthy Participants
NCT05901311
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
NCT05860933
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05841238
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
NCT05841277
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830
A Study of the Effect of Food on LY3537982 in Healthy Participants
NCT05824858
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
NCT05810597
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
NCT05778864
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
NCT05757531
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
NCT05706506
A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants
NCT05749848
A Study of LY3848575 in Healthy Participants
NCT05727072
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
NCT05696847
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
NCT05662332
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
NCT05372419
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
NCT05369403
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
NCT05630196
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
NCT05644353
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
NCT05564039
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
NCT05563246
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
NCT05620563
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT05616013
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
NCT05611957
A Study of LY3305677 in Participants With Obesity Or Overweight
NCT05623839
A Study of Effect of LY3556050 on Metformin in Healthy Participants
NCT05615467
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
NCT05620576
A Study of LY3457263 in Obese Participants
NCT05582096
A Drug Interaction Study of LY3871801 in Healthy Participants
NCT05602675
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
NCT05565742
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.